Drugs / SCB-1019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06194318 | Dec 2023 → Feb 2025 | respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-03-25 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults cloverbiopharma.com ↗
Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover’s RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY |
| 2025-10-14 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults cloverbiopharma.com ↗
Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover’s RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults previously receiving an initial dose of AREXVY |
| 2025-03-24 | Clover Biopharmaceuticals AUS Pty | Regulatory Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 cloverbiopharma.com ↗
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced IND clearance by U.S. FDA and that enrollment of the first participants has been completed in a Phase I revaccination clinical trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate based on Clover's Trimer-Tag vaccine technology platform. |
| 2024-10-29 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY cloverbiopharma.com ↗
Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) |
| 2024-06-18 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Preliminary PhaseⅠResults for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults cloverbiopharma.com ↗
Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively |
| 2024-04-08 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort cloverbiopharma.com ↗
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194318 ↗ |
| Modality | Vaccine | “The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).” NCT06194318 ↗ |